This Article Full Text Full Text (PDF) An erratum has been published eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Friedlander, M. Articles by Grogan, M. Search for Related Content PubMed PubMed Citation Articles by Friedlander, M. Articles by Grogan, M.

Guidelines for the Treatment of Recurrent and Metastatic Cervical Cancer

Department of Medical Oncology, Prince of Wales Hospital, Randwick, New South Wales, Australia

Correspondence: Michael Friedlander, M.D., Department of Medical Oncology, Prince of Wales Hospital, High Street Randwick NSW 2031, Australia. Telephone: 612-9382-2606; Fax: 612-9382-2588; e-mail: m.friedlander{at}unsw.edu.au

Although there have been important advances in the management of women with cervical cancer, the optimal treatment for patients with locally recurrent and metastatic disease is still problematic, and there are relatively few randomized trials to guide treatment decisions. This paper reviews the approach to management of patients who relapse after primary treatment for cervical cancer. Patients who are still potentially curable with radical treatment are identified, and the various treatment strategies are discussed. However, most women are treated with palliative intent, and the literature on palliative management is reviewed together with the levels of evidence.

Key Words. Recurrent • Metastatic • Cervical cancer • Treatment

This article has been cited by other articles:

				A. A.M. van der Veldt, M. R. Buist, M. W. van Baal, E. F. Comans, O. S. Hoekstra, and C. F.M. Molthoff Clarifying the Diagnosis of Clinically Suspected Recurrence of Cervical Cancer: Impact of 18F-FDG PET J. Nucl. Med., December 1, 2008; 49(12): 1936 - 1943. [Abstract] [Full Text] [PDF]

				N. Reesink-Peters, J. van der Velden, K. A. ten Hoor, H. M. Boezen, E. G.E. de Vries, M. S. Schilthuis, M. J.E. Mourits, H. W. Nijman, J. G. Aalders, H. Hollema, et al. Preoperative Serum Squamous Cell Carcinoma Antigen Levels in Clinical Decision Making for Patients With Early-Stage Cervical Cancer J. Clin. Oncol., March 1, 2005; 23(7): 1455 - 1462. [Abstract] [Full Text] [PDF]